On November 15, 2023, Edward Chan, a Class II director designated by 1315 Capital II, L.P. to the board of directors (the ?Board?) of Interpace Biosciences, Inc. (the ?Company?), provided notice to the Company of his resignation from the Board, effective immediately. Mr. Chan?s notice was not the result of any disagreement with the Company on any matters relating to the Company?s operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.45 USD | +3.57% | +2.84% | +34.26% |
05-09 | Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-07 | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M | MT |
1st Jan change | Capi. | |
---|---|---|
+34.26% | 6.34M | |
-8.99% | 5.89B |
- Stock Market
- Equities
- IDXG Stock
- News Interpace Biosciences, Inc.
- Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director